Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference
28 Settembre 2023 - 1:00PM
Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a
commercial-stage biotechnology company focused on the discovery,
development and commercialization of genetic medicines to treat
diseases with high unmet medical needs, announced today that the
Company will participate in the Chardan 7th Annual Genetic
Medicines Conference in New York.
Krish Krishnan, Chairman and Chief Executive Officer, will
participate in a fireside chat during the conference and host
investor meetings on October 3.
A webcast of the presentation will be available here beginning
at 11:30 am ET on Tuesday, October 3 and will
be posted on the Investor section of the
Company’s website.
About Krystal Biotech, Inc.Krystal Biotech,
Inc. (NASDAQ: KRYS) is a commercial-stage biotechnology company
focused on the discovery, development and commercialization of
genetic medicines to treat diseases with high unmet medical needs.
VYJUVEK™ is the Company’s first commercial product, the
first-ever redosable gene therapy, and the only medicine approved
by the FDA for the treatment of dystrophic epidermolysis bullosa.
The Company is rapidly advancing a robust preclinical and clinical
pipeline of investigational genetic medicines in respiratory,
oncology, dermatology, ophthalmology, and aesthetics. Krystal
Biotech is headquartered in Pittsburgh, Pennsylvania. For more
information, please visit http://www.krystalbio.com, and follow
@KrystalBiotech on LinkedIn and Twitter.
CONTACTInvestors and
Media:
Meg Dodge
Krystal Biotech
mdodge@krystalbio.com
Grafico Azioni Krystal Biotech (NASDAQ:KRYS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Krystal Biotech (NASDAQ:KRYS)
Storico
Da Giu 2023 a Giu 2024